Infection disease screening and follow-up in CAR-T therapy recipients. Journey of a patient undergoing cell therapy with CAR-Ts, with emphasis on the need for preinfusion screening, considering endemic diseases, and previous exposure. After lymphodepletion (day –5 to day –3) and infusion (day 0), the patient goes through all the expected stages of therapy with damage to the immune system and greater susceptibility to infectious agents, requiring long-term follow-up. Anti–IL-6, anti–interleukin-6; D-5, day –5; ID, infectious disease. Figure created with BioRender.com.